Crystal Structure of the Retinoblastoma Protein N Domain Provides Insight into Tumor Suppression, Ligand Interaction, and Holoprotein Architecture

Molecular Cell

Volumn 28, Issue 3, 2007, Pages 371-385

  Hassler, Markus ^a   Singh, Shradha ^a   Yue, Wyatt W ^a   Luczynski, Maciej ^a   Lakbir, Rachid ^a   Sanchez Sanchez, Francisco ^c   Bader, Thomas ^b,d   Pearl, Laurence H ^a   Mittnacht, Sibylle ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSERM   (France)

^c University of Castilla La Mancha   (Spain)

^d INSTITUT COCHIN   (France)

Author keywords

CELLCYCLE

Indexed keywords

LIGAND; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; MUTATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; REPRESSOR PROTEINS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 35648942123     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2007.08.023     Document Type: Article

References (52)

1. Andersen G., Poterszman A., Egly J.M., Moras D., and Thierry J.C. The crystal structure of human cyclin H. FEBS Lett. 397 (1996) 65-69
2. Batsche E., Desroches J., Bilodeau S., Gauthier Y., and Drouin J. Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness. J. Biol. Chem. 280 (2005) 19746-19756
3. Binne U.K., Classon M.K., Dick F.A., Wei W., Rape M., Kaelin Jr. W.G., Naar A.M., and Dyson N.J. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat. Cell Biol. 9 (2007) 225-232
4. Blanquet V., Turleau C., Gross M.S., Goossens M., and Besmond C. Identification of germline mutations in the RB1 gene by denaturant gradient gel electrophoresis and polymerase chain reaction direct sequencing. Hum. Mol. Genet. 2 (1993) 975-979
5. Blanquet V., Turleau C., Gross-Morand M.S., Senamaud-Beaufort C., Doz F., and Besmond C. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Hum. Mol. Genet. 4 (1995) 383-388
6. Bork P., Hofmann K., Bucher P., Neuwald A.F., Altschul S.F., and Koonin E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11 (1997) 68-76
7. Brichard B., Heusterspreute M., De Potter P., Chantrain C., Vermylen C., Sibille C., and Gala J.L. Unilateral retinoblastoma, lack of familial history and older age does not exclude germline RB1 gene mutation. Eur. J. Cancer 42 (2006) 65-72
8. Brown N.R., Noble M.E., Endicott J.A., Garman E.F., Wakatsuki S., Mitchell E., Rasmussen B., Hunt T., and Johnson L.N. The crystal structure of cyclin A. Structure 3 (1995) 1235-1247
9. Chan H.M., Smith L., and La Thangue N.B. Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene 20 (2001) 6152-6163
10. Choubey D., and Lengyel P. Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J. Biol. Chem. 270 (1995) 6134-6140
11. Classon M., and Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2 (2002) 910-917
12. Dahiya A., Gavin M.R., Luo R.X., and Dean D.C. Role of the LXCXE binding site in Rb function. Mol. Cell. Biol. 20 (2000) 6799-6805
13. Dick F.A., Sailhamer E., and Dyson N.J. Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins. Mol. Cell. Biol. 20 (2000) 3715-3727
14. Dryja T.P., Rapaport J., McGee T.L., Nork T.M., and Schwartz T.L. Molecular etiology of low-penetrance retinoblastoma in two pedigrees. Am. J. Hum. Genet. 52 (1993) 1122-1128
15. Durfee T., Mancini M.A., Jones D., Elledge S.J., and Lee W.H. The amino-terminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J. Cell Biol. 127 (1994) 609-622
16. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
17. Frank R., and Overwin H. SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol. Biol. 66 (1996) 149-169
18. Goo Y.H., Na S.Y., Zhang H., Xu J., Hong S., Cheong J., Lee S.K., and Lee J.W. Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation. J. Biol. Chem. 279 (2004) 7131-7135
19. Goodrich D.W. How the other half lives, the amino-terminal domain of the retinoblastoma tumor suppressor protein. J. Cell. Physiol. 197 (2003) 169-180
20. Hensey C.E., Hong F., Durfee T., Qian Y.W., Lee E.Y., and Lee W.H. Identification of discrete structural domains in the retinoblastoma protein. Amino-terminal domain is required for its oligomerization. J. Biol. Chem. 269 (1994) 1380-1387
21. Jakubowska A., Zajaczek S., Haus O., Limon J., Kostyk E., Krzystolik Z., and Lubinski J. Novel RB1 gene constitutional mutations found in Polish patients with familial and/or bilateral retinoblastoma. Hum. Mutat. 18 (2001) 459
22. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J., and Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995) 313-320
23. Krissinel, E., and Henrick, K. (2005). Detection of protein assemblies in crystals. In Computational Life Sciences: First International Symposium, CompLife 2005, Konstanz, Germany, September 25-27, 2005. (Berlin/Heidelberg: Springer), pp. 163-174.
24. Krutzfeldt M., Ellis M., Weekes D.B., Bull J.J., Eilers M., Vivanco M.D., Sellers W.R., and Mittnacht S. Selective ablation of retinoblastoma protein function by the RET finger protein. Mol. Cell 18 (2005) 213-224
25. Lee J.O., Russo A.A., and Pavletich N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391 (1998) 859-865
26. Lee C., Chang J.H., Lee H.S., and Cho Y. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes Dev. 16 (2002) 3199-3212
27. Lefevre S.H., Chauveinc L., Stoppa-Lyonnet D., Michon J., Lumbroso L., Berthet P., Frappaz D., Dutrillaux B., Chevillard S., and Malfoy B. A T to C mutation in the polypyrimidine tract of the exon 9 splicing site of the RB1 gene responsible for low penetrance hereditary retinoblastoma. J. Med. Genet. 39 (2002) E21
28. Leslie A.G. The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 48-57
29. Li Y., Wang X., Zhang X., and Goodrich D.W. Human hHpr1/p84/Thoc1 regulates transcriptional elongation and physically links RNA polymerase II and RNA processing factors. Mol. Cell. Biol. 25 (2005) 4023-4033
30. Liu Z., Song Y., Bia B., and Cowell J.K. Germline mutations in the RB1 gene in patients with hereditary retinoblastoma. Genes Chromosomes Cancer 14 (1995) 277-284
31. Lohmann D.R., Gerick M., Brandt B., Oelschlager U., Lorenz B., Passarge E., and Horsthemke B. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am. J. Hum. Genet. 61 (1997) 282-294
32. MacLellan W.R., Xiao G., Abdellatif M., and Schneider M.D. A novel Rb- and p300-binding protein inhibits transactivation by MyoD. Mol. Cell. Biol. 20 (2000) 8903-8915
33. Mittnacht S. The retinoblastoma protein-from bench to bedside. Eur. J. Cell Biol. 84 (2005) 97-107
34. Miyake S., Sellers W.R., Safran M., Li X., Zhao W., Grossman S.R., Gan J., DeCaprio J.A., Adams P.D., and Kaelin Jr. W.G. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol. Cell. Biol. 20 (2000) 8889-8902
35. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
36. Nikolov D.B., Chen H., Halay E.D., Usheva A.A., Hisatake K., Lee D.K., Roeder R.G., and Burley S.K. Crystal structure of a TFIIB-TBP-TATA-element ternary complex. Nature 377 (1995) 119-128
37. Noble M.E., Endicott J.A., Brown N.R., and Johnson L.N. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem. Sci. 22 (1997) 482-487
38. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
39. Qian Y., Luckey C., Horton L., Esser M., and Templeton D.J. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol. Cell. Biol. 12 (1992) 5363-5372
40. Riley D.J., Liu C.Y., and Lee W.H. Mutations of N-terminal regions render the retinoblastoma protein insufficient for functions in development and tumor suppression. Mol. Cell. Biol. 17 (1997) 7342-7352
41. Rubin S.M., Gall A.L., Zheng N., and Pavletich N.P. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123 (2005) 1093-1106
42. Sanchez F., Mateu E., Beneyto M., Najera C., and Prieto F. A constitutional homozygous mutation in the RB1 gene in a patient with unilateral retinoblastoma. J. Med. Genet. 37 (2000) 615-620
43. Sanchez-Sanchez F., Ramírez-Castillejo C., Weekes D.B., Beneyto M., Prieto F., Mittnacht S., and Najera C. Attenuation of disease phenotype through alternative translation initiation in low penetrance retinoblastoma. Hum. Mutat. 28 (2007) 159-167
44. Shao Z., Siegert J.L., Ruppert S., and Robbins P.D. Rb interacts with TAF(II)250/TFIID through multiple domains. Oncogene 15 (1997) 385-392
45. Sterner J.M., Dew-Knight S., Musahl C., Kornbluth S., and Horowitz J.M. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol. Cell. Biol. 18 (1998) 2748-2757
46. Terwilliger T.C., and Berendzen J. Evaluation of macromolecular electron-density map quality using the correlation of local r.m.s. density. Acta Crystallogr. D Biol. Crystallogr. 55 (1999) 1872-1877
47. Udvadia A.J., Templeton D.J., and Horowitz J.M. Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. Proc. Natl. Acad. Sci. USA 92 (1995) 3953-3957
48. Xiao B., Spencer J., Clements A., Ali-Khan N., Mittnacht S., Broceno C., Burghammer M., Perrakis A., Marmorstein R., and Gamblin S.J. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc. Natl. Acad. Sci. USA 100 (2003) 2363-2368
49. Xu H.J., Xu K., Zhou Y., Li J., Benedict W.F., and Hu S.X. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc. Natl. Acad. Sci. USA 91 (1994) 9837-9841
50. Yamane K., Katayama E., Sugasawa K., and Tsuruo T. Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity. Oncogene 19 (2000) 1982-1991
51. Yamane K., Katayama E., and Tsuruo T. p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb. Oncogene 20 (2001) 2859-2867
52. Yang H., Williams B.O., Hinds P.W., Shih T.S., Jacks T., Bronson R.T., and Livingston D.M. Tumor suppression by a severely truncated species of retinoblastoma protein. Mol. Cell. Biol. 22 (2002) 3103-3110